April 30, 2014
Chugai Pharmaceutical said on April 24 that it has ceased the multinational PIII METLung study of its anti-Met humanized monoclonal antibody onartuzumab in patients with non-small cell lung cancer (NSCLC). The move comes after Swiss parent Roche announced in early...read more